Radiotherapy review on National Surgical Adjuvant Breast and Bowel Project(NSABP) phase III breast cancer clinical trials - Is there a need for submission of portal/simulation films?

Citation
M. Deutsch et al., Radiotherapy review on National Surgical Adjuvant Breast and Bowel Project(NSABP) phase III breast cancer clinical trials - Is there a need for submission of portal/simulation films?, AM J CL ONC, 22(6), 1999, pp. 606-608
Citations number
1
Categorie Soggetti
Oncology
Journal title
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
ISSN journal
02773732 → ACNP
Volume
22
Issue
6
Year of publication
1999
Pages
606 - 608
Database
ISI
SICI code
0277-3732(199912)22:6<606:RRONSA>2.0.ZU;2-I
Abstract
In all National Surgical Adjuvant Breast and Bowel Project (NSABP) breast c ancer trials in which patients are treated with lumpectomy and postoperativ e breast irradiation, the quality assurance requirements dictate submission of a completed radiotherapy data form with the stated administered doses, the volumes treated, treatment prescription and daily treatment record shee ts, dosimetry and calculation sheets, isodose distributions on the breast c ontour, photos of the patient in the treatment position, and portal or simu lation films. A review of radiotherapy data on 1,982 patients who had lumpe ctomies accrued to seven recent NSABP breast cancer studies revealed only 2 patients who were judged to have inadequate fields. In both cases, a very small portion of the breast tissue was not included in the irradiated volum e as demonstrated by the submitted films. On this basis, it was argued that submission of portal or simulation films for patients receiving postlumpec tomy breast irradiation is not necessary. However, there was concern as to the incidence of patients with a possible excess amount of lung tissue incl uded in the irradiated volume. To address this concern, the amount of irrad iated lung was determined for the first 208 patients who had lumpectomies, with submitted data entered into the recent NSABP pathologic node-positive protocol B-28. Current NSABP radiation therapy guidelines suggest limiting the thickness of the irradiated lung in the portal beams to less than or eq ual to 3 cm. Only two patients (<1%) were found to have >3 cm of irradiated lung tissue in the treatment volume. Portal film submission is a considera ble inconvenience to the individual institutions and is costly in terms of shipping, handling, and storage. These results indicate that submission of portal films is not a necessary part of quality assurance in NSABP breast c ancer protocols. The NSABP has therefore eliminated the requirement for rou tine submission of portal films in protocols for which radiotherapy is not part of the rest question.